An open randomised trial of second-line endocrine therapy in advanced breast cancer: Comparison of the aromatase inhibitors letrozole and anastrozole

European Journal of Cancer

Volumn 39, Issue 16, 2003, Pages 2318-2327

  Rose, C ^a   Vtoraya, O ^b   Pluzanska, A ^c   Davidson, N ^d   Gershanovich, M ^e   Thomas, R ^f   Johnson, S ^g   Caicedo, J J ^h   Gervasio, H ⁱ   Manikhas, G ^j   Ben Ayed, F ^k   Burdette Radoux, S ^l   Chaudri Ross, H A ^m   Lang, R ^m  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Russian Federation   (Russian Federation)

^c Regional Oncology Centre Bydgoszcz   (Poland)

^d NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^e N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h Instituto Nacional de Cancerología   (Colombia)

ⁱ Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^j City Oncology Dispensary St Petersburg   (Russian Federation)

^k SALAH AZAIEZ INSTITUTE   (Tunisia)

^l ROYAL VICTORIA HOSPITAL   (Canada)

^m NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Anastrozole; Aromatase inhibitors; Breast cancer; Endocrine therapy; Letrozole

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPNEA; ENZYME INHIBITION; FEMALE; HUMAN; INHIBITION KINETICS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE; TREATMENT FAILURE; VISCERA;

EID: 10744222368     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00630-0     Document Type: Article

References (27)

1. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr.-Relat. Cancer. 8:2001;191-195.
2. Goss P.E., Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol. 19:2001;881-894.
3. Buzdar A., Jonat W., Howell A.et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer. results of overview analysis of two phase III trials J Clin Oncol. 14:1996;2000-2011.
4. Buzdar A., Douma J., Davidson N.et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. 19:2001;3357-3366.
5. Dombernowsky P., Smith I., Falkson G.et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer. double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate J. Clin. Oncol. 16:1998;453-461.
6. Gershanovich M., Chaudri H.A., Campos D.et al. Letrozole, a new oral aromatase inhibitor. randomized trial comparing 2.5 mg daily, 0.5 mg daily, and aminoglutethimide in postmenopausal women with advanced breast cancer Ann. Oncol. 9:1998;639-645.
7. Jonat W., Howell A., Blomqvist C.et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer. 32A:1996;404-412.
8. Kaufmann M., Bajetta E., Dirix L.Y.et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer. results of a phase III randomized double-blind trial J. Clin. Oncol. 18:2000;1399-1411.
9. Bhatnagar A.S., Brodie A.M.H., Long B.J.et al. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J. Steroid. Biochem. Mol. Biol. 76:2001;199-202.
10. Miller W.R., Dixon J.M. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control. 9:2002;9-15.
11. Bhatnagar A.S., Hausler A., Schieweck K.et al. Estrogen depletion in advanced breast cancer why, how and where are we going? Rubens R.D. Advanced Breast Cancer: Reassessing Hormonal Therapy. 2000;21-32 Parthenon, New York.
12. Brodie A., Lu Q., Liu Y., Long B., Wang J.-P., Yue W. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology. 12(Suppl. 5):1998;36-40.
13. Geisler J., Haynes B., Anker G., Dowsett M., Lønning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 20:2002;751-757.
14. Buzdar A., Jonat W., Howell A.et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. results of a survival update based on a combined analysis of data from two mature phase III trials Cancer. 83:1998;1142-1152.
15. Rose C., Vtoraya O., Pluzanska A.et al. Letrozole (Femara) vs. anastrozole (Arimidex). second-line treatment in postmenopausal women with advanced breast cancer Proc. Am. Soc. Clin. Oncol. 21:2002;34a. (abstr 131).
16. Lachin J.M., Foulkes M.A. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 42:1986;507-519.
17. Santen R.J., Harvey H.A. Use of aromatase inhibitors in breast carcinoma. Endocr.-Relat. Cancer. 6:1999;75-92.
18. Lønning P.E. New endocrine Drugs for treatment of advanced breast cancer. Acta Oncol. 29:1990;379-386.
19. Dowsett M., Geisler J., Haynes B.P., Anker G., Lønning P.E. Letrozole achieves more complete inhibition of whole body aromitization than anastrozole. Eur. J. Cancer. 36(Suppl. 5):2000;S88. (abstr 221).
20. Lønning P.E. Stepwise estrogen suppression manipulating the estrostat. J. Steroid Biochem. Mol. Biol. 79:2001;127-132.
21. Bonneterre J., Buzdar A., Nabholtz J.M.et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. results of two randomized trials designed for combined analysis Cancer. 92:2001;2247-2258.
22. Nabholtz J.M., Buzdar A., Pollak M.et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. results of a North American multicenter randomized trial J. Clin. Oncol. 18:2000;3758-3767.
23. Mouridsen H., Sun Y., Gershanovich M.et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women. Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J. Clin. Oncol. 21:2003;2101-2109.
24. Eiermann W., Paepke S., Appfelstaedt J.et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole. a randomized double-blind multicenter study Ann Oncol. 12:2001;1527-1532.
25. Ellis M.J., Coop A., Singh B.et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1- and/or erbB-2-positive, estrogen receptor-positive primary breast cancer. evidence from a phase III randomized trial J. Clin. Oncol. 19:2001;3808-3816.
26. Dixon J.M., Love C.D.B., Renshaw L.et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr.-Relat. Cancer. 6:1999;227-230.
27. Begg C., Cho M., Eastwood S.et al. Improving the quality of reporting of randomised controlled trials. the CONSORT statement JAMA. 276:1996;637-639.